Why Is Sanofi Stock Falling Thursday?

Sanofi's stock tumbled 8.59% after its potential Dupixent successor, amlitelimab, met Phase 3 endpoints but fell short of benchmark efficacy expectations, notably Dupixent's performance. While amlitelimab's efficacy was less robust than Dupixent, it exhibited a superior safety profile (1.1% pyrexia, 0.4% chills) compared to Amgen's rocatinlimab (10% pyrexia, 6% chills), enabling higher dosing and comparable efficacy to rocatinlimab. This outcome raises doubts about Sanofi's ability to sustain its dermatology franchise post-patent expiry, as OX40/OX40L therapies are now seen as potentially limited to second-line treatment, reducing their market potential.

Analysis

Sanofi's (SNY) stock registered a sharp 8.59% decline following the release of Phase 3 trial results for amlitelimab, its intended successor to the blockbuster drug Dupixent. Although the drug met all primary and key secondary endpoints for atopic dermatitis, its efficacy fell short of the high benchmark set by Dupixent, which demonstrated a roughly 36% improvement on EASI-75 over placebo. This outcome has led analysts to reposition the entire anti-OX40/OX40L drug class, including Amgen's (AMGN) rocatinlimab, as likely second-line treatments for patients who fail on first-line IL-13/4 therapies. A key differentiating factor emerged in the safety profiles: amlitelimab showed significantly lower rates of pyrexia (1.1%) and chills (0.4%) compared to rocatinlimab (10% and 6%, respectively). This superior safety profile allowed amlitelimab to achieve efficacy comparable to rocatinlimab, which was forced to cap its dosing in Phase 3 due to side effects. The results cast significant doubt on Sanofi's ability to fully replace Dupixent's revenue upon its patent expiration, suggesting a smaller market opportunity for amlitelimab despite its more favorable dosing schedule.

Key Decisions for Investors

• Investors should recalibrate long-term revenue forecasts for Sanofi, as amlitelimab is now positioned as a second-line therapy, significantly reducing its peak sales potential as a Dupixent successor.
• The data presents a competitive headwind for Amgen, as its rocatinlimab candidate shows a clear safety and dosing disadvantage relative to Sanofi's amlitelimab within the OX40 drug class.
• Consider the reduced total addressable market for the OX40/OX40L class; while there is room for new mechanisms, their inability to match Dupixent's efficacy likely limits their commercial upside to a smaller, post-IL-13/4 patient population.